Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.